The ongoing shortages of tirzepatide and other popular weight-loss drugs have allowed for compounded versions of the treatments with similar or related ingredients to hit the market, with less oversight and regulation from the US Food and Drug Administration
A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients
The strategy reflects a major industry shift: treating obesity as a core biological disease alongside cardiovascular, rare, and neurodegenerative conditions
However, in October 2024, the FDA declared the tirzepatide drug shortage over, so no compounded tirzepatide could be sold after March 19, 2025
[26] De Rose, Aldo, Mantica, et al, Supporting the role of penile trauma and micro-trauma in the etiology of Peyronies disease
Short-term stool softener or osmotic agent if lifestyle steps arent enoughask your clinician